Neurosom wins patent for personalized EEG modeling method

Neurosom has secured a U.S. patent for a Bayesian method that combines personal EEG data with brain atlas models to sharpen brain-activity mapping and guide transcranial electrical stimulation. The company says the technology could improve diagnostics, personalize treatment and support its sleep-focused brain health platform.

Why it matters: - The patent gives Neurosom a protected method for making EEG source analysis more precise. - The company says the technology could improve how clinicians identify brain activity patterns and tailor stimulation-based therapies. - Better brain-activity mapping could support earlier diagnosis, more targeted treatment and dementia-risk reduction efforts.

What happened: - Neurosom announced the issuance of U.S. Patent No. 12,663,866 on July 9, 2026. - The patent covers a method titled “Method for Bayesian Super-Resolution of Electroencephalographic Source Analysis and Transcranial Electrical Stimulation.” - The method combines Bayesian statistical modeling, personal EEG data and established brain atlas models. - The company says the system is designed to create “super-resolution” views of the origins of brain electrical activity.

The details: - The invention uses prior knowledge of brain architecture, including cortical column anatomy and fiber tractography, as Bayesian priors. - Neurosom says the approach can upscale 280-channel HDEEG/EIT measurements into very high-density solutions. - The company cites a jump from roughly 9,600 cortical sources to cortical macrocolumns. - Neurosom says the method can help clinicians and researchers compare results against normative datasets. - CEO Viral Sheth said the breakthrough enables a more personalized understanding of brain function and supports individualized treatment programs. - Neurosom specializes in precision brain health solutions built around high-density EEG, AI-driven software analytics and continuous at-home monitoring. - The company’s Sleep WISP wearable device is part of that platform. - Neurosom says Sleep WISP supports early diagnosis, lifestyle optimization and neuromodulation therapies. - Neurosom was founded in 2021. - The company says Sleep WISP measures EEG sleep cycles at home and delivers personalized, painless electrical stimulation using AI-powered, FDA-cleared software. - Neurosom says the platform is aimed at extending deep and REM sleep, which the company links to plaque clearance associated with neurodegenerative diseases.

Between the lines: - The patent strengthens Neurosom’s position in personalized neurophysiological modeling at a time when precision medicine is gaining traction. - The method also ties brain mapping more closely to sleep therapy, which is the company’s core commercial focus. - The company is framing the patent as both a research tool and a clinical differentiator. - Sheth said the technology could improve diagnostics and guide interventions to help prevent dementia and other age-related neurological disorders.

What's next: - Neurosom is likely to build future products and clinical workflows around the patented modeling approach. - The company says the next step is more accurate brain activity mapping that can inform targeted interventions. - Neurosom will continue positioning Sleep WISP and its analytics platform around sleep optimization, brain health and neuromodulation.

The bottom line: - Neurosom now has a patent-backed method that could make EEG analysis more personalized and more clinically useful.